{"id":36403,"date":"2023-08-29T12:38:23","date_gmt":"2023-08-29T10:38:23","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=36403"},"modified":"2024-05-17T15:02:47","modified_gmt":"2024-05-17T13:02:47","slug":"making-clinical-trials-relevant-to-stroke-survivors","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/neuroscience\/making-clinical-trials-relevant-to-stroke-survivors\/","title":{"rendered":"Making clinical trials relevant to stroke survivors"},"content":{"rendered":"\n

At Ipsen, we endeavor for all our clinical trials to be reflective of the real world, and this requires the participation of a cross-section of people living with a particular condition. However, for some stroke survivors with post-stroke spasticity \u2013 a condition that can cause stiffness in the muscles following a stroke \u2013 there can be significant barriers that get in the way of them participating in clinical trials.<\/p>\n\n\n\n

To address the potential barriers of participation in the EPITOME study, which will investigate the onset of \u2018problematic\u2019 post-stroke spasticity that would benefit from treatment, we sought feedback from stroke survivors and a caregiver on the design of the study and how it could be optimized to suit their needs. The panel also helped us to better understand the experiences of stroke survivors with post-stroke spasticity and their caregivers.<\/p>\n\n\n\n

The insights obtained through the patient panel have helped to shape the way the trial will be run. Changes to the study design, as a result of the insights, include:<\/p>\n\n\n\n